The largest and most ethnically diverse study of its kind has identified 697 genetic variants linked to major depressive disorder (MDD). The research also highlights potential therapies for ...

Incorporating dynamic pricing into cost-effectiveness analysis could offer significant benefits for equity in health care. The life cycle of a drug encompasses phases of market exclusivity, ...

Neumora Therapeutics, Inc. (NMRA) is gearing up to report results from one of its phase 3 studies, which is using its drug Navacaprant for the treatment of patients with major depressive disorder (MDD ...

Patients with asthma and major depressive disorder had more negative beliefs about their asthma, worse treatment adherence ...

Patients who experienced a formulary-related rejection of cariprazine for adjunctive treatment of major depressive disorder had significantly higher hospitalization rates than those with approved ...